GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biotika AS (XBRA:1BSL01AE) » Definitions » Price-to-Owner-Earnings

Biotika AS (XBRA:1BSL01AE) Price-to-Owner-Earnings : 88.46 (As of May. 25, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Biotika AS Price-to-Owner-Earnings?

As of today (2024-05-25), Biotika AS's share price is €23.00. Biotika AS's Owner Earnings per Share (TTM) ended in Dec. 2022 was €0.26. It's Price-to-Owner-Earnings for today is 88.46.


The historical rank and industry rank for Biotika AS's Price-to-Owner-Earnings or its related term are showing as below:

XBRA:1BSL01AE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.19   Med: 5.62   Max: 92.02
Current: 87.45

During the past 13 years, the highest Price-to-Owner-Earnings of Biotika AS was 92.02. The lowest was 2.19. And the median was 5.62.


XBRA:1BSL01AE's Price-to-Owner-Earnings is ranked worse than
86.09% of 417 companies
in the Drug Manufacturers industry
Industry Median: 27.13 vs XBRA:1BSL01AE: 87.45

As of today (2024-05-25), Biotika AS's share price is €23.00. Biotika AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €1.03. Therefore, Biotika AS's PE Ratio for today is 22.42.

As of today (2024-05-25), Biotika AS's share price is €23.00. Biotika AS's EPS without NRI for the trailing twelve months (TTM) ended in was €0.84. Therefore, Biotika AS's PE Ratio without NRI for today is 27.25.

During the past 13 years, Biotika AS's highest PE Ratio without NRI was 521.13. The lowest was 6.38. And the median was 15.24.


Biotika AS Price-to-Owner-Earnings Historical Data

The historical data trend for Biotika AS's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotika AS Price-to-Owner-Earnings Chart

Biotika AS Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.28 5.35 4.63 - 87.45

Biotika AS Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 87.45 -

Competitive Comparison of Biotika AS's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Biotika AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotika AS's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biotika AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Biotika AS's Price-to-Owner-Earnings falls into.



Biotika AS Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Biotika AS's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=23.00/0.26
=88.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotika AS  (XBRA:1BSL01AE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Biotika AS Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Biotika AS's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotika AS (XBRA:1BSL01AE) Business Description

Traded in Other Exchanges
N/A
Address
Slovenskc Lupca 566, Banská Bystrica, SVK, 976 13
Biotika AS is a manufacturer of pharmaceutical preparations for the human and veterinary application. It is engaged in the production of Active Pharmaceutical Ingredients (API), contract manufacturing of API, and contract manufacturing of final dosage formulations. It also offers research and development services. It manufacturers Polymyxine B Sulfate and other API for third parties (toll manufacturing) of pharmaceutical quality. Biotika is well known as a reliable manufacturer of high-quality pharmaceutical preparations for the human as well as veterinary application and also as a very important producer of the feed additives for breeding farm animals.

Biotika AS (XBRA:1BSL01AE) Headlines

No Headlines